Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid sub-study
IntroductionExtended adjuvant endocrine therapy for breast cancer with aromatase inhibitors may potentially alternate the lipid profile of postmenopausal patients and thus augmentation the risk of developing cardiovascular disease. In this study, a sub-protocol of the ATENA (Adjuvant post-Tamoxifen Exemestane versus Annihilation Applied) trial, we compared the effect of the steroidal aromatase inactivator exemestane on the lipid profile of postmenopausal patients with operable breast cancer in the adjuvant setting, to that of observation alone following completion of five to seven years leading treatment with tamoxifen. Methods: In this open-label, randomized, duplicate group study, 411 postmenopausal patients with operable breast cancer who have been treated with tamoxifen for 5 to 7 years, were randomized to either 5 supplementary senility of exemestane (25mg/day;
The spatial distribution of radiodense breast tissue: a longitudinal study
IntroductionMammographic breast density is one of the strongest celebrated markers of susceptibility to breast cancer. To period trial into density has relied on a unmarried measure (for example, percent density (PD)) summarising the guideline calm of density for the complete breast, with no consideration of how the radiodense tissue may be distributed. This interpret aims to investigate the spatial distribution of density within the breast using 493 mammographic images from a example of 165 premenopausal women (~3 medio-lateral indirect views per woman). Methods: Each breast image was divided into 48 regions and the PD for the full breast (overall PD) and for each one of its regions (regional PD) was estimated.
Frequent loss of endothelin-3 EDN3 expression due to epigenetic inactivation in human breast cancer
IntroductionEndothelin signalling plays a crucial role in cell differentiation, proliferation and migration processes. There is compelling evidence that altered endothelin signalling is involved in carcinogenesis by modulating cell survival and promoting invasiveness. To date, most reports retain focussed on the oncogenic prepatent of endothelin-1 (EDN1) and EDN2, both of which are overexpressed in various tumor entities. Here, we aimed at a first comprehensive discussion on EDN3 expression and its implication in human breast cancer. Methods: EDN3 mRNA expression was assessed by Northern blotting in methodical human tissues (n=9), as well as in matched pairs of ordinary and tumourous tissues from breast specimens (n=50).
Full length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer
IntroductionWe evaluated whether CK19, one of the leading cytoskeleton proteins of epithelial cells, is released as full-length protein from viable tumor cells and if this belongings is meaningful for metastatic succession in breast cancer patients. Methods: EPISPOT (EPithelial ImmunoSPOT) assays were performed to analyze the proceeds of full-length CK19 by carcinoma cells of different origins, and the sequence of CK19 was analysed by mass spectrometry. More functional experiments with cycloheximide, brefeldin A or vincristine were done to analyse the biol of the CK19-release. CK19-EPISPOT was used to detect disseminated tumour cells in bone soul (BM) of 45 breast cancer patients who were then followed over a median of 6 years.
Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours
IntroductionThe term of supplementary genes, other than estrogen receptor (ER), may be determining to the hormone-responsive phenotype of breast cancer. Microarray analyzes have revealed that forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA-3) are expressed in speedy partnership with ER-alpha, both encoding for transcription factors with a inherent involvement in the ER-alpha-mediated process in breast cancer. The head of this glance at was to explore whether the expression of FOXA1 and GATA-3 may feed an circumstance to stratify subsets of patients that could keep better outcome, among the ER-alpha-negative/poor prognosis breast cancer group. Methods: We evaluate FOXA1 and GATA-3 signal in 249 breast carcinomas by immunohistochemistry, associating it with breast cancer molecular markers, clinicopathological features and patient'
Sex steroids, growth factors and mammographic density: a cross-sectional study of UK post-menopausal Caucasian and Afro-Caribbean women
IntroductionSex steroids, insulin-like flowering factors (IGF) and prolactin are breast cancer risk factors on the contrary whether their effects are mediated finished mammographic density, one of the strongest risk factors for breast cancer, is unknown. Whether such a hormonal rationale of mammographic density exists, hormones may underlie ethnic differences in both mammographic density and breast cancer incidence rates. Methods: In a cross-sectional study of 270 post-menopausal Caucasian and Afro-Caribbean women attending a population-based breast screening avail in London UK, we investigated if plasma biomarkers (oestradiol, oestrone, masculinity hormone binding globulin (SHBG), testosterone, prolactin, leptin, insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein 3 (IGFBP3)) were related to and explained ethnic differences in percent density, dense area and non-dense area, measured in Cumulus using the entrance method.
Estrogen regulation of apoptosis- how can one hormone stimulate and inhibit?
The link between estrogen and the development and proliferation of breast cancer is well documented. Estrogen stimulates cultivation and inhibits apoptosis through estrogen receptor-mediated mechanisms in crowded cell types. Interestingly, there is energetic evidence that estrogen induces apoptosis in breast cancer and other cell types. Fourty years ago, before the development of tamoxifen, high-dose estrogen was used to induce tumour regression of hormone-dependent breast cancer in post-menopausal women. While the mechanisms by which estrogen induces apoptosis were not completely known, modern evidence from our laboratory and others demonstrates the involvement of the extrinsic (Fas/FasL) and the intrinsic (mitochondria) pathways in this process.
WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth
IntroductionIn breast cancer deregulation of the WNT signaling method occurs by autocrine mechanisms. WNT ligands and Frizzled (FZD) receptors are coexpressed in primary breast tumors and cancer cell lines. Moreover, diverse breast tumors pageant hypermethylation of secreted Frizzled-related protein 1 (sFRP1)' s promoter region, causing low expression of this WNT antagonist. We have previously shown that the WNT pathway influences proliferation of breast cancer cell lines via activation of canonical signaling and epidermal aggrandizement factor receptor (EGFR) transactivation, and that interference with WNT signaling reduces proliferation. Here we see the role of WNT signaling in breast tumor cell migration and on xenograft outgrowth.
HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005
IntroductionClassification of breast cancers according to the HER-2 oncogene status is of central force in the choice of post-surgical therapies. A decrease in the proportion of HER-2 positive breast cancer has been suspected, nevertheless no material on the incidence trends at population common include been reported. Methods: We studied the proportion of HER-2 positive breast cancers by chromogenic in situ hybridization (CISH) in three cohorts (years 1982 to 1986 (n=310), 1989 to 1992, (n=108), and 2004 to 2005 (n=713) in the population of the Pirkanmaa infirmary district (approximately 220, 000 women). Cancer incidence rates were age-adjusted to the world customary population.
Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid sub-study
IntroductionExtended adjuvant endocrine therapy for breast cancer with aromatase inhibitors may potentially exchange the lipid profile of postmenopausal patients and thus enlargement the risk of developing cardiovascular disease. In this study, a sub-protocol of the ATENA (Adjuvant post-Tamoxifen Exemestane versus Aught Applied) trial, we compared the effect of the steroidal aromatase inactivator exemestane on the lipid profile of postmenopausal patients with operable breast cancer in the adjuvant setting, to that of observation alone next completion of five to seven years valuable treatment with tamoxifen. Methods: In this open-label, randomized, paralell group study, 411 postmenopausal patients with operable breast cancer who have been treated with tamoxifen for 5 to 7 years, were randomized to either 5 additional years of exemestane (25mg/day;
